Back to top
more

BioRad Laboratories (BIO)

(Delayed Data from NYSE)

$276.80 USD

276.80
530,933

-7.80 (-2.74%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $276.78 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

Zacks Equity Research

Change Healthcare (CHNG) Q4 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

Change Healthcare's (CHNG) fiscal fourth-quarter results benefit from solid performance across Software and Analytics, Network Solutions and Technology-Enabled segments.

Zacks Equity Research

Cooper Companies (COO) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.

Zacks Equity Research

Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect a solid show by its segments and robust product portfolio.

Zacks Equity Research

Wall Street Analysts Believe Bio-Rad (BIO) Could Rally 53%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 52.9% in Bio-Rad (BIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

If You Invested $1000 in Bio-Rad Laboratories 10 Years Ago, This Is How Much You'd Have Now

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Zacks Equity Research

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.

Zacks Equity Research

Bio-Rad Laboratories (BIO) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Bio-Rad (BIO) delivered earnings and revenue surprises of 76.43% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More

by Urmimala Biswas

Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.

Zacks Equity Research

Bio-Rad (BIO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Robust uptake of dPCR products and a rebound in routine testing are likely to have contributed to Bio-Rad's (BIO) first-quarter top line.

Zacks Equity Research

Here's Why You Should Retain Bio-Rad (BIO) Stock For Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) owing to a recovery in most of its key global markets as well as an uptick in demand for COVID-related products.

Zacks Equity Research

Illumina (ILMN) Launches Genomic Solution Hub in Brazil

by Zacks Equity Research

Illumina's (ILMN) customers and partners in Brazil currently span basic research, applied markets to clinical labs and healthcare institutions.

Zacks Equity Research

Here's Why You Should Retain SmileDirectClub (SDC) For Now

by Zacks Equity Research

Investors are optimistic about SmileDirectClub's (SDC) series of cutting-edge innovation, strategic distribution and insurance partnerships.

Zacks Equity Research

Bruker (BRKR) Unveils New Imaging Tools for Cancer Research

by Zacks Equity Research

Bruker's (BRKR) latest innovation for cancer research is likely to strengthen the company's opportunities in proteomics and spatial biology.

Zacks Equity Research

Alcon (ALC) Stock Rallies 4.7% Since Posting Q4 Earnings Beat

by Zacks Equity Research

Alcon (ALC) stock rallies on robust growth across all Surgical and Vision Care sales categories.

Zacks Equity Research

Here's Why You Should Hold on to Walgreens Boots (WBA) For Now

by Zacks Equity Research

Investors are optimistic about Walgreens (WBA) owing to the recent product launches.

Zacks Equity Research

Henry Schein (HSIC) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) owing to favorable dental business trends and a strong solvency position.

Zacks Equity Research

Here's Why You Should Invest In Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) owing to the favorable dental business trends.

Zacks Equity Research

Here's Why You Should Hold on to Chemed (CHE) Stock For Now

by Zacks Equity Research

Investors are optimistic about robust performance by Chemed's (CHE) Roto-Rooter arm.

Zacks Equity Research

Walgreens (WBA) Expands Medical Care Offerings in California

by Zacks Equity Research

Walgreens' (WBA) new initiative is intended to reduce care gaps and advance care management by providing access to more affordable and convenient services.

Zacks Equity Research

Bruker (BRKR) to Support Biopharma Industries With New Buyout

by Zacks Equity Research

Bruker's (BRKR) recent buyout strengthens the company as a key software and solutions provider for small molecule, biologics and new drug modalities pharma companies.

Zacks Equity Research

Medtronic (MDT) Innovations Aid Global Growth, Volume Woe Stays

by Zacks Equity Research

In the neuroscience portfolio, Medtronic (/MDT) is gaining market share in Cranial and Spinal technologies.

Zacks Equity Research

Abbott (ABT) Aveir VR Leadless Pacemaker Receives FDA Nod

by Zacks Equity Research

Abbott's (ABT) Aveir VR is a leadless pacemaker designed to treat patients with slow heart rhythms in the United States.

Zacks Equity Research

STERIS (STE) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on impressive growth across its operating segments.

Zacks Equity Research

Here's Why You Should Retain CVS Health (CVS) Stock For Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) owing to continued progress in its consumer-centric digital solutions.

Zacks Equity Research

Bio-Rad (BIO) Thrives on Global Sales and Testing Uptake

by Zacks Equity Research

Bio-Rad's (BIO) underlying Life Science business' core revenues grow on strong uptake of Droplet Digital PCR as well as the qPCR business.